Patents expiring, what Pfizer, Astrazeneca, Eli Lilly, Merck and more risk

AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rival

AstraZeneca has great ambitions for its mid-stage oral cholesterol drug, believing that it could reach peak sales of more than $5 billion. Positive data presented Monday at the American College of Cardiology meeting bring that ...

Patents expiring, what Pfizer, Astrazeneca, Eli Lilly, Merck and more risk

From Pfizer to Astrazeneca, passing through Eli Lilly, Merck and other Big Pharma. Starting this year, the patents of some of the best-selling drugs will expire. This is how much the arrival of generic versions on the market will weigh on pharmaceutical companies. Facts, names and numbers Not just weight loss drugs. Also seeing their patents expire soon are 8 key drugs produced by some of the largest pharmaceutical companies, who may have to dea…